Nicox SA : * Announces acquisition of its U.S. ophthalmic diagnostics subsidiary, Nicox Inc., by Valeant Pharmaceuticals International, Inc.* Transaction worth up to $20 million, including $10 million upfront cash payment plus potential sales-based milestone payments of up to $10 million* Valeant has acquired most of Nicox commercial infrastructure in U.S. associated with diagnostics* Nicox has retained a number of U.S.-based employees focused on therapeutics
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 1.75% or $2.31/share to $134.21. In the past year, the shares have traded as low as $105.17 and as high as $153.10. On average, 2526030 shares of VRX exchange hands on a given day and today's volume is recorded at 2117625.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.88% or $1.32/share to $151.47. In the past year, the shares have traded as low as $110.26 and as high as $170.45. On average, 468460 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 359439.
Source
